Related Experiment Video
Updated: Mar 11, 2026

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity
Xiaodong Ding1, Sandeep K Barodia2, Lisha Ma1
1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract:
Dominantly inherited mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common causes of familial Parkinson's disease (PD) and LRRK2 polymorphisms are associated with increased risk for idiopathic PD. However, the molecular mechanisms by which these mutations cause PD remain uncertain. In vitro studies indicate that disease-linked mutations in LRRK2 increase LRRK2 kinase activity and LRRK2-mediated cell toxicity. Identifying LRRK2-interacting proteins and determining their effects on LRRK2 are important for understanding LRRK2 function and for delineating the pathophysiological mechanisms of LRRK2 mutations. Here we identified a novel protein, F-box and leucine-rich repeat domain-containing protein 18 (Fbxl18) that physically associates with LRRK2. We demonstrated that Fbxl18 is a component of a Skp1-Cullin1-F-box ubiquitin ligase complex that regulates the abundance of LRRK2 by selectively targeting phosphorylated LRRK2 for ubiquitination and proteasomal degradation. Knockdown of endogenous Fbxl18 stabilized LRRK2 abundance while protein kinase C activation enhanced LRRK2 degradation by Fbxl18. Dephosphorylation of LRRK2 blocked Fbxl18 association with LRRK2. Taken together, we have identified potential mechanisms for LRRK2 regulation by kinase signaling pathways. Furthermore, Fbxl18 prevented caspase activation and cell death caused by LRRK2 and PD-linked mutant LRRK2. This reveals novel targets for developing potential therapies for familial and idiopathic PD.
Insights
Researchers discovered a new protein, Fbxl18, that regulates leucine-rich repeat kinase 2 (LRRK2) levels. This finding offers potential new therapeutic targets for Parkinson's disease (PD).
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Dominant LRRK2 mutations are a leading cause of familial Parkinson's disease (PD).
- LRRK2 polymorphisms increase idiopathic PD risk, but mechanisms remain unclear.
- Disease-linked LRRK2 mutations elevate kinase activity and cell toxicity.
Purpose of the Study:
- To identify LRRK2-interacting proteins to understand LRRK2 function and PD pathogenesis.
- To elucidate the role of novel interacting proteins in regulating LRRK2 levels and activity.
Main Methods:
- Identification of LRRK2-interacting proteins using co-immunoprecipitation.
- Characterization of Fbxl18 as a component of a Skp1-Cullin1-F-box ubiquitin ligase complex.
- Assessment of Fbxl18's effect on LRRK2 ubiquitination, degradation, and cell toxicity.
Main Results:
- Fbxl18 physically associates with LRRK2 and targets phosphorylated LRRK2 for degradation.
- Fbxl18 knockdown increases LRRK2 abundance; protein kinase C activation enhances LRRK2 degradation.
- Fbxl18 protects against cell death induced by wild-type and mutant LRRK2.
Conclusions:
- Fbxl18 regulates LRRK2 protein levels through a ubiquitin-proteasome pathway.
- Kinase signaling pathways modulate LRRK2 abundance via Fbxl18-mediated degradation.
- Fbxl18 represents a potential therapeutic target for familial and idiopathic Parkinson's disease.
More Related Videos
08:55Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
Published on: December 14, 2017
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Targeted Cancer Therapies
There are several types of targeted therapies against...